Do COVID-19 Infections Result in a Different Form of Secondary Hemophagocytic Lymphohistiocytosis

Raymond Chu,Charmaine van Eeden,Sneha Suresh,Wendy I Sligl,Mohammed Osman,Jan Willem Cohen Tervaert
DOI: https://doi.org/10.3390/ijms22062967
2021-03-15
Abstract:The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in significant morbidity and mortality across the world, with no current effective treatments available. Recent studies suggest the possibility of a cytokine storm associated with severe COVID-19, similar to the biochemical profile seen in hemophagocytic lymphohistiocytosis (HLH), raising the question of possible benefits that could be derived from targeted immunosuppression in severe COVID-19 patients. We reviewed the literature regarding the diagnosis and features of HLH, particularly secondary HLH, and aimed to identify gaps in the literature to truly clarify the existence of a COVID-19 associated HLH. Diagnostic criteria such as HScore or HLH-2004 may have suboptimal performance in identifying COVID-19 HLH-like presentations, and criteria such as soluble CD163, NK cell activity, or other novel biomarkers may be more useful in identifying this entity.
What problem does this paper attempt to address?